What the Research Says
Saccharomyces Boulardii is a well-documented probiotic yeast with demonstrated efficacy across various clinical applications. As a yeast, it uniquely resists antibacterial antibiotics, making it an ideal adjunct during antibiotic therapy to prevent antibiotic-associated diarrhea (AAD). A systematic review and meta-analysis by Szajewska et al. (2015) found that S. boulardii significantly reduces the risk of AAD with a number needed to treat (NNT) of 10, highlighting its preventive potential.
In addition to AAD prevention, studies have explored its role in managing acute diarrhea and preventing Clostridioides difficile recurrence. McFarland et al. (2010) conducted a systematic review supporting its efficacy in reducing the duration of pediatric acute diarrhea and lowering the risk of recurrent episodes. Furthermore, S. boulardii has been shown to enhance Helicobacter pylori eradication rates when used as an adjuvant therapy. A meta-analysis by Liu et al. (2023) involving 15 RCTs with 2156 participants found that its supplementation improved eradication success and reduced adverse events in children.
Recent studies have also highlighted its benefits in neonatal care, with Gao et al. (2021) reporting that S. boulardii supplementation significantly reduced the incidence of necrotizing enterocolitis (NEC) and feeding intolerance in pre-term infants. These findings underscore its potential as a preventive measure in vulnerable populations.
Overall, Saccharomyces Boulardii stands out as a versatile probiotic with well-documented benefits across multiple clinical settings, supported by rigorous evidence from systematic reviews and meta-analyses.
